NCT06470633View on ClinicalTrials.gov

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions

Breast CancerHR+/HER2- Breast Cancer

Interventions

DRUG

Adebrelimab

Adebrelimab 1200mg iv q3w

PROCEDURE

High Intensity Focused Ultrasoun（HIFU）

HIFU treatment at lesion site

DRUG

Cyclophosphamide

600mg/m2 iv q3w

DRUG

Epirubicin

90mg/m2 iv q3w

DRUG

Docetaxel

75mg/m2 iv q3w

All Listed Sponsors

collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06470633 - To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | Biotech Hunter | Biotech Hunter